Healthcare
Live Price
Offline$0.60
+0.00% today
1Y Change
-47.83%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 252 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sonendo, Inc. (SONX) is a Healthcare stock with listed on OTC. The stock last traded around $0.60 and down 47.8% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -27.7%, EPS growth of +9.2%, a dividend yield of 0.0%. What stands out right now is revenue -27.7%, EPS +9.2%, free cash flow +47.2% with operating margin -92.6% and ROIC -120.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SONX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SONX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SONX Max Drawdown
-98.26%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SONX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$23.4M
-29.7% YoY
FY Net Income
-$46.7M
+3.8% YoY
Free Cash Flow
-$39.5M
+22.0% YoY
Revenue Growth
-27.7%
EPS Growth
+9.2%
Gross Margin
37.4%
Net Margin
-88.4%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 32M | 44M | 42M | 33M | 23M |
| Gross Profit | 12M | 11M | 10M | 8M | 4M |
| Operating Income | -29M | -58M | -58M | -44M | -43M |
| EBITDA | -27M | -55M | -51M | -41M | -39M |
| Net Income | -28M | -61M | -57M | -48M | -47M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10M | 14M | 18M | 85M | 52M |
| Total Assets | 31M | 78M | 137M | 115M | 76M |
| Total Liabilities | 26M | 50M | 55M | 43M | 330M |
| Shareholder Equity | 5M | 28M | 82M | 72M | -254M |
| Total Debt | 19M | 40M | 39M | 29M | 32M |
| Net Debt | 9M | 26M | 21M | -55M | -20M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
39M
+20.7% YoY
Capital Expenditures
916K
+53.6% YoY
Free Cash Flow
39M
+22.0% YoY
Key ratios
Gross Margin
37.4%
Operating Margin
-92.6%
Net Margin
-88.4%
ROE
-166.8%
Debt / Equity
3.65x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.